LOGIN  |  REGISTER
Amneal Pharmaceuticals
Cue Biopharma

Illumina To Webcast Upcoming Investor Conference

December 16, 2025 | Last Trade: US$137.60 2.82 2.09

SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:

Upcoming Investor Conference

  • 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

The presentation is scheduled for 7:30 a.m. PT (10:30 a.m. ET), with a Q&A session to follow at approximately 7:50 a.m. PT (10:50 a.m. ET).

The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com. A replay will be archived on Illumina's website for at least 30 days following the event.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Investors:
Conor McNamara
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Christine Douglass
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page